Effectiveness of Reboxetine in Treatment of Outpatient Children and Adolescents with Attention DeficitHyperactivity Disorder with Comorbid Anxiety Disorders
,
Abstract
Objective: Some previous studies have reported that ADHD is often comorbid with anxiety disorders. The aim of the present study was to evaluate the effectiveness of reboxetine in treating outpatient children
and adolescents with ADHD and comorbid anxiety disorders.
Method: In this open-label study, 25 outpatient children and adolescents, aged 6-16 years were selected by convenient sampling and underwent treatment with 4mg reboxetine for four weeks. Data were collected at baseline, two weeks and four weeks after the start of the medication using Conners' Parent Questionnaire, Hamilton's Rating Scale for Anxiety, Clinical Global Assessment Scale, Clinical Global Impression-Severity Scale and Side Effects Form. Data were
analyzed using repeated measure, analyses of variance (ANOVA), Tukey post hoc test and paired t-test.
Results: There were significant reduction in the total score of ADHD (F = 31.441; P <0.001) at the end of the treatment compared to baseline (Table1). The differences between T0 and T2 in the subscales of attention deficit, hyperactivity and confrontation (F = 20.691; P <0.001, F = 28.810; P <0.001, and F = 17.463; P <0.001, respectively) were also significant. Findings also indicated significant differences between T0 and T1 (P<0.01) and T1 and T2 (P<0.01) in all of the subscales except for confrontation. A significant improvement was observed in the severity of ADHD and anxiety disorders during different courses of the treatment (p<0.001). No significant changes were observed in systolic and diastolic blood pressure and pulse and weight of the patients during the study. The most common complications were headache and anorexia.
Conclusions: The short-term treatment with reboxetine was effective in improving ADHD with comorbid anxiety disorders. Therefore, reboxetine could be used as a treatment option for ADHD in those children who experience comorbid anxiety disorders or in those who are non-responsive or intolerant to methylphenidate.
Wilens TE, Spencer TJ. Understanding attention-deficit/hyperactivity disorder from childhood to adulthood. Postgrad Med 2010; 122: 97-109.
Ek U, Westerlund J, Holmberg K, Fernell E. Academic performance of adolescents with ADHD and other behavioural and learning problems -a population-based longitudinal study. Acta Paediatr 2010; 100: 402-406.
Banaschewski T, Roessner V, Dittmann RW, Santosh PJ and Rothenberger A. Non-Stimulant Medications in the Treatment of Adhd. Eur Child Adolesc Psychiatry 2004; 13 Suppl 1: I102-116.
Pliszka SR. Non-stimulant treatment of attention-deficit/hyperactivity disorder. CNS Spectr 2003; 8: 253-8.
Biederman J, Faraone SV, Spencer T, et al. Patterns Of Psychiatric Co morbidity, Cognition, And Psycho Social functioning in Adults with Attention Deficit Hyperactivity Disorder .Am J psychiatry 1993; 150: 1792 - 1798.
Biederman J, Faraone S, Milberger S, Guite J, Mick E, Chen L, et al. A Prospective 4-Year Follow-up Study of Attention-Deficit Hyperactivity and Related Disorders. Arch Gen Psychiatry1996; 53: 437-446.
Prasad S, Furr AJ, Zhang S, Ball S, Allen AJ. Baseline values from the electrocardiograms of children and adolescents with ADHD. Child Adolesc Psychiatry Ment Health 2007; 1: 11.
Garnock-Jones KP, Keating GM. Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents. Paediatr Drugs. 2009; 11: 203-226.
Hong J, Dilla T and Arellano J. A Modelled Economic Evaluation Comparing Atomoxetine with Methylphenidate in the Treatment of Children with Attention-Deficit/Hyperactivity Disorder in Spain. BMC Psychiatry 2009; 9: 15.
Arabgol F, Panaghi L, Hebrani P. Reboxetine versus methylphenidate in treatment of children and adolescents with attention deficit-hyperactivity disorder. Eur Child Adolesc Psychiatry 2009; 18: 53-59.
Cohen-Yavin I, Yoran-Hegesh R, Strous RD, Kotler M, Weizman, Spivak B. Efficacy of Reboxetine in the Treatment of Attention-Deficit/Hyperactivity Disorder in Boys with Intolerance to Methylphenidate: An Open-Label, 8-Week, Methylphenidate-Controlled Trial. Clin Neuropharmacol 2009; 32: 179-182.
Tehrani-Doost M, Moallemi S, Shahrivar Z. An open-label trial of reboxetine in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2008; 18: 179-184.
Toren P, Ratner S, Weizman A, Lask M, Ben-Amitay G and Laor N. Reboxetine Maintenance Treatment in Children with Attention-Deficit/Hyperactivity Disorder: A Long-Term Follow-up Study. Journal of child and adolescent psychopharmacology 2007; 17: 803-812.
Cak HT, Cetin FC. Reboxetine use in the treatment of attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2006; 16: 803-804.
Ratner S, Laor N, Bronstein Y, Weizman A, Toren P. Six-week open-label reboxetine treatment in children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2005; 44: 428-433.
Mozes T, Meiri G, Ben Amity G, Sabbagh M, Weizman A. Reboxetine as an optional treatment for hyperkinetic conduct disorder: a prospective open-label trial. J Child Adolesc Psychopharmacol 2005; 15: 259-269.
Otka JE, Mercadante MT, Scahill L and Leckman JF. Reboxetine as a Potentially Effective Treatment for Attention Deficit Hyperactivity Disorder. J Child Adolesc Psychopharmacol 2001; 11: 203-204.
Riahi F, Tehrani-Doost M, Shahrivar Z, Alaghband-Rad J. Efficacy of reboxetine in adults with attention-deficit/hyperactivity disorder: A randomized, placebo-controlled clinical trial. Hum Psychopharmacol 2010; 25: 570–576.
Conners KC. Conners Rating Scales Manual. New York: Multi-Health; 1997.
Shahaeian A, Shahim S, Bashash L, usofi F. Standardization, factor analysisandreliability of the short form of Conner's parent rating scalefor6 to 11years old childreninShiraz. Educational Psychological studies 2007; 3: 97-120.
Dyrborg J, Larsen FW, Nielsen S, Byman J, Nielsen BB and Gautre-Delay F. The Children's Global Assessment Scale (Cgas) and Global Assessment of Psychosocial Disability (Gapd) in Clinical Practice--Substance and Reliability as Judged by Intraclass Correlations. Eur Child Adolesc Psychiatry 2000; 9: 195-201.
Shaffer D, Gould MS, Brasic J, Ambrosini P, Fisher P, Bird H, et al. A Children's Global Assessment Scale (Cgas). Arch Gen Psychiatry 1983; 40: 1228-1231.
Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959; 32: 50-55.
Andreescu C, Belnap BH, Rollman BL, Houck P, Ciliberti C, Mazumdar S, et al. Generalized anxiety disorder severity scale validation in older adults. Am J Geriatr Psychiatry 2008; 16: 813-818.
Freeman JB, GareiaAM, Leonard HL. Anexity disorders. In: Lewis M. Child and adolescent psychiatry: a comprehensive text book new haven. New York: Williams and Wilkins; 2002.
McDowell I. Measurement Health, A Guide to Rating Scales and Questionnaires, 3th eds. New York: Oxford University Press; 2006.
Biederman J, Spencer T, Wilens T. Evidence –based pharmacotherapy for attention –deficit hyper activity disorder. Int J Neuropsychopharmacol 2004; 7: 77-97.
Schuler P, Seibel K, Chevts V and Schaffler K. [Analgesic Effect of the Selective Noradrenaline Reuptake Inhibitor Reboxetine]. Nervenarzt 2002; 73: 149-154.
Versiani M, Cassano G, Perugi G, Benedetti A, Mastalli L, Nardi A, et al. Reboxetine, a Selective Norepinephrine Reuptake Inhibitor, Is an Effective and Well-Tolerated Treatment for Panic Disorder. J Clin Psychiatry 2002; 63: 31-37.
Tashakori A, Arablgol F, Panahy L. Effect of Reboxetine on Reduction of Anxiety Symptoms in Depressed Children and Adolescents. Scientific Medical Journal 2006; 6: 210 – 218 .
Kasper S, EI Giamal N, Hilger E. Reboxetine: The first selective noradrenalin reuptake inhibitor. Expert Opin Pharmacother 2000; 1: 771-782.
Taner E, Demir EY, Cosar B. Comparison of the effectiveness of reboxetine versus fluoxetine in patients with atypical depression: a single-blind, randomized clinical trial. AdvTher. 2006; 23: 974-987.
Valentini V, Frau R, Di Chiara G. Noradernalin Transporter Blockers raise Extracellular dopamine In Medial Prefrontal but not Parietal and Occipital Context: Differences With mianserin and Clozapin . J Neurochem 2004; 88: 917-927.
Spencer T, Biederman J, Wilens T, et al. Pharmacotherapy of attention deficit hyperactivity disorder across the Life cycle. J Am Acad Child Adolesc Psychiatry 1996; 35: 409-432.
Taylor E, Dopfner M, Sergeant J, Asherson P, Banaschewski T, Buitelaar J, et al. European Clinical Guidelines for Hyperkinetic Disorder -- First Upgrade. Eur Child Adolesc Psychiatry 2004; 13 Suppl 1: I7-30.
Labellarte MJ, Crosson JE, Riddle MA. The relevance of prolonged QTc measurement to pediatric psychopharmacology. J Am Acad Child Adolesc Psychiatry 2003; 42: 642-450.
Taner E, Demir EY, Cosar B. Comparison of the effectiveness of reboxetine versus fluoxetine in patients with atypical depression: a single-blind, randomized clinical trial. Adv Ther 2006: 23; 974-987.
| Files | ||
| Issue | Vol 8 No 4 (2013) | |
| Section | Articles | |
| Keywords | ||
| Attention deficit-hyperactivity disorder (ADHD) Conners’ Parent questionnaire Hamilton’s Anxiety Rating Scale Reboxetine | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
